UPDATE: Citigroup Upgrades PAREXEL International to Buy on Operational Improvement, Valuation

Citigroup raised its rating on PAREXEL International PRXL from Neutral to Buy and increased its price target from $34 to $36. Citigroup commented, "We are upgrading PRXL to Buy with a $36 price target (+$2) based on: a misunderstood press release issued December 27th to announce a modest acquisition that is favorable, improving core operational metrics & related read-through to its major big pharma partnership implementation, and recent pullback in valuation. We also note $100mn worth of remaining share repurchase authorization as the initial $100mn buyback concludes that may create a near term catalyst. Net, we believe the mix of positive data points together with a more palatable valuation creates a favorable risk/reward profile for investors." PAREXEL International closed at $29.21 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPre-Market OutlookAnalyst RatingsCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!